Venetoclax, Homoharringtonine, Azacitidine G-CSF AML Study
Summary
ClinicalTrials.gov registered a Phase 1/2 clinical study (NCT07507825) investigating the combination of Venetoclax, Homoharringtonine, Azacitidine, and G-CSF for the treatment of Acute Myeloid Leukemia (AML). The trial is registered in the ClinicalTrials.gov database maintained by the National Library of Medicine. No regulatory obligations or policy changes are associated with this registration.
What changed
ClinicalTrials.gov recorded a new clinical trial registration (NCT07507825) for a study evaluating Venetoclax, Homoharringtonine, Azacitidine, and G-CSF in AML patients. The registration includes standard trial metadata such as intervention details, eligibility criteria, and study objectives. This is a routine registration entry with no policy implications.
This is a standard clinical trial registration with no compliance deadlines or required actions for regulated entities. Sponsors and investigators conducting applicable clinical trials must ensure compliance with FDAAA 801 registration requirements under 42 CFR Part 11.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.